{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:04:40Z","timestamp":1771553080032,"version":"3.50.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>Several pediatric Hodgkin lymphoma (HL) consortia have demonstrated safe omission of radiotherapy (RT) in early stage HL, whereas feasibility of omitting RT in advanced HL is still under investigation. This is a single institution retrospective analysis of 27 patients with intermediate-risk or high-risk HL (age 22\u2009y and younger), treated with a modification of the dose-intensive OEPA-COPDAC (vincristine, etoposide, prednisone, doxorubicin\u2014cyclophosphamide, vincristine, prednisone, dacarbazine) regimen, with radiation restricted to only sites of inadequate early response (Deauville \u22653 and\/or \u226475% tumor shrinkage). Their outcome was compared with a historical cohort (n=42) treated with Stanford V or ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), who received consolidative involved-field RT. RT was omitted in 15 of 27 (56%) of patients treated with OEPA-COPDAC, majority of whom (67%) had high-risk disease. At a median follow-up of 3.1 years, the 3-year progression-free survival was 100% in patients who received OEPA-COPDAC, versus 83.3% (95% confidence interval, 68.2%-91.7%) in the historical cohort, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.03. <jats:bold>O<\/jats:bold>ur analysis demonstrates excellent survival with omission of RT in more than 50% of patients with pediatric advanced HL, treated with a dose-intensive chemotherapy regimen. When administered, RT was restricted to only sites of inadequate early response. Results of large prospective studies are needed to validate these findings.<\/jats:p>","DOI":"10.1097\/mph.0000000000001076","type":"journal-article","created":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T11:51:20Z","timestamp":1514634680000},"page":"e338-e342","source":"Crossref","is-referenced-by-count":12,"title":["Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma"],"prefix":"10.1097","volume":"40","author":[{"given":"Nmazuo W.","family":"Ozuah","sequence":"first","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen J.","family":"Marcus","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorder\u2019s Center, Harvard Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute\/Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy L.","family":"Billett","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/cncr.28748","article-title":"Declining childhood and adolescent cancer mortality","volume":"120","author":"Smith","year":"2014","journal-title":"Cancer"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study","volume":"117","author":"Castellino","year":"2011","journal-title":"Blood"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood-2015-07-641035","article-title":"Hodgkin lymphoma in children and adolescents: improving the therapeutic index","volume":"126","author":"Kelly","year":"2015","journal-title":"Blood"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/jama.2012.5847","article-title":"Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma","volume":"307","author":"Metzger","year":"2012","journal-title":"Jama"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.2012.45.3266","article-title":"Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95","volume":"31","author":"Dorffel","year":"2013","journal-title":"J Clin Oncol"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children\u2019s Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","article-title":"Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin\u2019s lymphoma\u2014a report from the Children\u2019s Oncology Group","volume":"30","author":"Wolden","year":"2012","journal-title":"J Clin Oncol"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study","volume":"28","author":"Mauz-Korholz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"R10-20230918","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/annonc\/7.suppl_4.S105","article-title":"Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: an update","volume":"7","author":"Horning","year":"1996","journal-title":"Ann Oncol"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1748-717X-2-13","article-title":"A comparison of mantle versus involved-field radiotherapy for Hodgkin\u2019s lymphoma: reduction in normal tissue dose and second cancer risk","volume":"2","author":"Koh","year":"2007","journal-title":"Radiat Oncol (London, England)"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11864-015-0377-x","article-title":"Does radiation have a role in advanced stage Hodgkin\u2019s or non-Hodgkin lymphoma?","volume":"17","author":"Specht","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/pbc.24861","article-title":"The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma","volume":"61","author":"Maraldo","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/asheducation-2011.1.310","article-title":"Optimal therapy of advanced Hodgkin lymphoma","volume":"2011","author":"Advani","year":"2011","journal-title":"Hematol Am Soc Educ Program"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved-field radiotherapy for advanced Hodgkin\u2019s lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"N Engl J Med"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet (London, England)"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1200\/JCO.2005.03.2151","article-title":"Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519)","volume":"23","author":"Johnson","year":"2005","journal-title":"J Clin Oncol"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2967\/jnumed.113.130609","article-title":"Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients","volume":"55","author":"Rossi","year":"2014","journal-title":"J Nucl Med"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00247-012-2559-z","article-title":"FDG PET\/CT in children and adolescents with lymphoma","volume":"43","author":"Kluge","year":"2013","journal-title":"Pediatr Radiol"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"e0149072","DOI":"10.1371\/journal.pone.0149072","article-title":"Inter-reader reliability of early FDG-PET\/CT response assessment using the Deauville scale after 2 cycles of intensive chemotherapy (OEPA) in Hodgkin\u2019s lymphoma","volume":"11","author":"Kluge","year":"2016","journal-title":"PloS One"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00259-014-2715-9","article-title":"qPET\u2014a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma","volume":"41","author":"Hasenclever","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201808000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:17:36Z","timestamp":1695010656000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201808000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001076","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}